33.40Open68.30Pre Close3 Volume8 Open Interest360.00Strike Price10.05KTurnover77.52%IV2.70%PremiumMay 16, 2025Expiry Date26.09Intrinsic Value100Multiplier16DDays to Expiry9.01Extrinsic Value100Contract SizeAmericanOptions Type-0.6477Delta0.0069Gamma8.96Leverage Ratio-0.6173Theta-0.0956Rho-5.81Eff Leverage0.2570Vega
Madrigal Pharmaceuticals Stock Discussion
Can Madrigal's Rezdiffra Breakthrough in Cirrhosis Patients Transform Liver Disease Treatment?
📊⚡️📊
MDGL gained as much as 15.2% to a $294.44 intraday high after Wolfe lauded the company's breakthrough liver drug Rezdiffra, according to published reports.
The U.S. Food and Drug Administration approved Rezdiffra in March as the first treatment fornonalcoholic steatoh...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$